TARO-ANASTROZOLE TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

ANASTROZOLE

Available from:

TARO PHARMACEUTICALS INC

ATC code:

L02BG03

INN (International Name):

ANASTROZOLE

Dosage:

1MG

Pharmaceutical form:

TABLET

Composition:

ANASTROZOLE 1MG

Administration route:

ORAL

Units in package:

30

Prescription type:

Prescription

Therapeutic area:

ANTINEOPLASTIC AGENTS

Product summary:

Active ingredient group (AIG) number: 0128681001; AHFS:

Authorization status:

APPROVED

Authorization date:

2012-10-25

Summary of Product characteristics

_Taro-Anastrozole Product Monograph _
_Page 1 of 53 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TARO-ANASTROZOLE
Anastrozole Tablets
Tablet, 1 mg, Oral
Non-steroidal Aromatase Inhibitor
Taro Pharmaceuticals Inc.
Date of Initial Authorization:
130 East Drive
OCT 25, 2012
Brampton, Ontario
L6T 1C1
Date of Revision:
March 1, 2023
Submission Control No: 271438
_Taro-Anastrozole Product Monograph _
_Page 2 of 53 _
RECENT MAJOR LABEL CHANGES
7. WARNINGS AND PRECAUTIONS, Muscoloskeletal
03/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics:
............................................................................................................................
4
1.2
Geriatrics:
............................................................................................................................
4
2
CONTRAINDICATIONS
....................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................ 4
4
DOSAGE AND ADMINISTRATION
....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................................... 5
4.4
Administration
....................................................................................................................
5
4.5
Missed Dose
..................................